Immune Therapeutics Announces that Equity Partner, Cytocom, Inc., has Filed an Investigational New Drug Application to Conduct a Phase II Clinical Trial Evaluating CYTO-201 Treatment in COVID-19 Patients

Winter Park, FL., June 9, 2020, - Immune Therapeutics, Inc. (OTC PINK: IMUN), announced today that equity partner, Cytocom, Inc., has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to study CYTO-201 for the treatment of COVID-19. The submission has been reviewed by the COVID-19 Scientific/Technical Triage Team and has been assigned for review by the Division of Pulmonology, Allergy and Critical Care (DPACC), part of the Office of...

read more

Immune Therapeutics, Inc. to Collaborate with Cytocom, Inc. to Develop Therapies for COVID-19. Immune Therapeutics, Inc. Signs Binding Letter of Intent to Collaborate with Cytocom, Inc. to Develop Lodonal™ and Other Drugs for COVID-19; Other Drug Development Programs Also Moving Forward

ORLANDO, Florida, March 20, 2020 – Immune Therapeutics, Inc. (OTC PINK: IMUN) (“Immune” “IMUN” or the “Company”), Immune Therapeutics, Inc., a late-stage clinical biopharmaceutical company focused on the development and commercialization of highly innovative therapies for use in oncology, immunology and anti-inflammatory disease today announced the signing of a binding letter of intent to collaborate with Cytocom, Inc. (“Cytocom” or “CYTO”) for the development of Lodonal™ and IRT-101 for use...

read more


Mcap MediaWire - Costumer Service

Translate »